Clinical Trials Sponsored by Venus Concept

Total 293 results

Corcept Therapeutics

Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Concert Pharmaceuticals

Active, not recruiting

European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

Spain, Germany, Poland, France, Hungary
Concert Pharmaceuticals

Enrolling by invitation

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States, Canada
Corcept Therapeutics

Completed

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Adrenocortical Carcinoma

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Hepatic Impairment

United States
Corcept Therapeutics

Completed

Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

Metastatic Castration-Resistant Prostate Cancer

United States, United Kingdom
Corcept Therapeutics

Completed

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

Non-alcoholic Steatohepatitis (NASH) | Antipsychotic Induced Weight Gain

United States
Corcept Therapeutics

Completed

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Neoplasms | Cushing Syndrome

United States
Concert Pharmaceuticals

Completed

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States
Corcept Therapeutics

Completed

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

Solid Tumors

United States
Concert Pharmaceuticals

Completed

Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

Renal Impairment

United States
Concert Pharmaceuticals

Completed

Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

Health Volunteers

United States
Concert Pharmaceuticals

Completed

Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects

Health Volunteers

United States
Concert Pharmaceuticals

Completed

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

Alopecia Areata

United States
Concert Pharmaceuticals

Completed

A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers

Healthy Volunteers

United States
Corcept Therapeutics

Completed

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

Healthy

United States
Concert Pharmaceuticals

Completed

Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects

Healthy Volunteers

United States
Corcept Therapeutics

Completed

The Effect of CORT118335 on Olanzapine-Induced Weight Gain

Antipsychotic-induced Weight Gain

United Kingdom
Corcept Therapeutics

Terminated

Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome

Cushing Syndrome | Hypercortisolism

United States
Concert Pharmaceuticals

Completed

Food Effect Study of CTP-543 in Healthy Volunteers

Healthy

United States
Corcept Therapeutics

Completed

Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery

Cushing's Syndrome

United States
Corcept Therapeutics

Completed

CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Healthy

United Kingdom
Corcept Therapeutics

Terminated

A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

Psychosis | Psychotic Depression | Severe Major Depression With Psychotic Features

United States
Concert Pharmaceuticals

Completed

Open-Label Crossover Study Comparing CTP-543 to Jakafi®

Healthy

United States
Concert Pharmaceuticals

Completed

Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656

Healthy

Australia
Concert Pharmaceuticals

Completed

Multiple Ascending Dose Study in Healthy Volunteers

Healthy

Australia
Corcept Therapeutics

Terminated

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

Cushing's Syndrome

United States
Corcept Therapeutics

Completed

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Cushing's Syndrome

United States
Corcept Therapeutics

Completed

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome (SEISMIC)

Cushing's Syndrome

United States
Corcept Therapeutics

Completed

An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression

Psychotic Disorders | Major Depressive Disorder

Bulgaria, Croatia, Romania, Serbia
Corcept Therapeutics

Completed

A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression

Psychotic Disorders | Major Depressive Disorder

United States
Corcept Therapeutics

Completed

An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

Major Depressive Disorder

Bulgaria, Croatia, Romania, Former Serbia and Montenegro
Concert Pharmaceuticals

Completed

Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

Diabetic Nephropathy

United States
Corcept Therapeutics

Recruiting

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Nonalcoholic Steatohepatitis (NASH) | Metabolic Dysfunction-associated Steatohepatitis (MASH)

United States, Puerto Rico
Corcept Therapeutics

Active, not recruiting

Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas (GRADIENT)

Hypercortisolism

United States, Austria, Bulgaria, Germany, Israel, Italy, Poland, Romania, Spain
Corcept Therapeutics

Active, not recruiting

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (DAZALS)

Amyotrophic Lateral Sclerosis

United States, Belgium, Canada, France, Germany, Ireland, Netherlands, Poland, Spain, United Kingdom
Corcept Therapeutics

Terminated

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)

Metastatic Pancreatic Ductal Adenocarcinoma

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

Healthy

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

Healthy

United States
Corcept Therapeutics

Completed

Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome (RE-KLAIM)

Cushing's Syndrome
Concert Pharmaceuticals

Completed

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States, Canada
Concert Pharmaceuticals

Completed

Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

Hepatic Impairment

United States
Corcept Therapeutics

Terminated

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Concert Pharmaceuticals

Completed

Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers

Health Volunteers

United States
Corcept Therapeutics

Active, not recruiting

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States, Belgium, Canada, Italy, Spain
Corcept Therapeutics

Completed

A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers

Healthy

India
Concert Pharmaceuticals

Completed

Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects

Healthy Volunteers

United States
Corcept Therapeutics

Completed

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Cushing's Syndrome

Netherlands, United States, Hungary, Italy, United Kingdom
Corcept Therapeutics

Completed

CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Healthy

United Kingdom
Concert Pharmaceuticals

Completed

Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers

Healthy

United States

3

Subscribe